Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
88 results about "Dopamine agonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A dopamine receptor agonist (DA) is a compound that activates dopamine receptors. There are two families of dopamine receptors, D₂-like and D₁-like, and they are all G protein-coupled receptors. D₁- and D₅-receptors belong to the D₁-like family and the D₂-like family includes D₂, D₃ and D₄ receptors. The DA are used in Parkinson’s disease and, to a lesser extent, to treat depression, hyperprolactinemia and restless leg syndrome.
Methods of treating metabolic syndrome using dopamine receptor agonists
InactiveUS20080200453A1Relieve symptomsEffective treatmentBiocideMetabolism disorderDiseaseVascular disease
The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.
Owner:VEROSCI
Implantable polymeric device for sustained release of dopamine agonist
The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.
Owner:TITAN PHARMA
Parenteral formulations of dopamine agonists
InactiveUS20100035886A1Reducing elevated cardiovascular-related inflammatory factorReducing elevated cardiovascular-related inflammatory factorsBiocideMetabolism disorderParenteral nutritionParenteral Dosage Form
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
Owner:VEROSCI
Dopamine-agonist combination therapy for improving sleep quality
InactiveUS20050267176A1Useful in treatmentOrganic active ingredientsBiocideLimb dyskinesiaSedative agent
The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone.
Owner:SEPACOR INC
Parenteral Formulations of Dopamine Agonists
ActiveUS20090143390A1Reducing elevated cardiovascular-related inflammatory factorReducing elevated cardiovascular-related inflammatory factorsBiocideAntipyreticEnteral administrationParenteral Dosage Form
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents_useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
Owner:VEROSCI
Drug treatment for restless leg syndrome
A method for the treatment of Restless Leg Syndrome (RLS), which comprises administering an alpha2-agonist and a second agent selected from the group consisting of the dopamine agonists, opioids, benzodiazepines and the combination of L-DOPA plus a decarboxylase inhibitor.
Owner:BRECHT HANS MICHAEL
Methods of treating metabolic syndrome using dopamine receptor agonists
InactiveUS20050054652A1Prevent desensitizationMinimize desensitizationBiocideAnimal repellantsDiseaseHypertriglyceridemia
The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.
Owner:CINCOTTA ANTHONY H
Sublingual films
ActiveUS8414922B2Alleviating dyskinesiaEffectively alleviatedBiocideNervous disorderSexual functioningDopamine
The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Owner:SUNOVION PHARMA INC
Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
InactiveUS20070015763A1Opportunities decreaseSimple processBiocidePeptide/protein ingredientsAtypical antipsychoticZiprasidone
This invention relates to combinations of an atypical antipsychotic, for example ziprasidone, and a dopamine agonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from psychosis and movement disorders associated with Parkinson's disease and subcortical dementias.
Owner:PFIZER INC +1
Methods of identifying responders to dopamine agonist therapy
The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE / NE metabolites: dopamine / dopamine metabolites, (c) NE and serotonin, (d) NE / NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE / NE metabolites and serotonin metabolites, or (g) NE is / are greater than about 30% over normal level; or dopamine / dopamine metabolites are less than about 30% below normal; or said patient has hypertriglyceridemai and / or hypertension . The present invention is also directed to treating identified patients with dopamine agonist therapy.
Owner:VEROSCI
Dopamine-Agonist Combination Therapy For Improving Sleep Quality
The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.
Owner:WOODWARD SPECIALTY LLC
Compositions and uses
According to the invention there is provided a method of treating and / or preventing the symptoms of Parkinson's disease comprising delivering apomorphine, optionally in combination with levodopa and / or a dopamine agonist that is not apomorphine, wherein apomorphine is administered by inhalation.
Owner:VECTURA LTD
Method and composition for the treatment of lipid and glucose metabolism disorders
InactiveUS20020187985A1Improved modification and regulationImprovement of one or more metabolic indicesBiocideAnimal repellantsBlood plasmaPlasma insulin
Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D1 dopamine agonist in conjunction with a dopamine D2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D1 dopamine agonist and the D2 dopamine agonist is conducted at a predetermined time.
Owner:VEROSCI
Method and composition for the treatment of lipid and glucose metabolism disorders
InactiveUS20010016582A1Improved modification and regulationImprovement of one or more metabolic indicesBiocideCarbohydrate active ingredientsBlood plasmaPlasma insulin
Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D1 dopamine agonist in conjunction with a dopamine D2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D1 dopamine agonist and the D2 dopamine agonist is conducted at a predetermined time.
Owner:CINCOTTA ANTHONY H
Parenteral formulations of dopamine agonists
ActiveUS8741918B2Reducing elevated cardiovascular-related inflammatory factorsBiocideAntipyreticParenteral nutritionParenteral Dosage Form
Owner:VEROSCI
Methods of identifying responders to dopamine agonist therapy
The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE / NE metabolites:dopamine / dopamine metabolites, (c) NE and serotonin, (d) NE / NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE / NE metabolites and serotonin metabolites, or (g) NE is / are greater than about 30% over normal level; or dopamine / dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg / dl and / or said patient has blood pressure of greater than about 135 / 85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy.
Owner:CINCOTTA ANTHONY H
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE / NE metabolites: dopamine / dopamine metabolites, (c) NE and serotonin, (d) NE / NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE / NE metabolites and serotonin metabolites, or (g) NE is / are greater than about 30% over normal level; or dopamine / dopamine metabolites are less than about 30% below normal; or said patient has hypertriglyceridemai and / or hypertension . The present invention is also directed to treating identified patients with dopamine agonist therapy.
Owner:VEROSCI
Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
ActiveUS8877708B2Eliminate side effectsImprove blood sugar controlPeptide/protein ingredientsMetabolism disorderPhases of clinical researchDopamine agonist
Owner:VEROSCI
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Owner:VEROSCI
Sublingual films
ActiveUS20120195955A1Alleviating dyskinesiaEffectively alleviatedBiocideNervous disorderDiseaseSexual dysfunction
The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Owner:SUNOVION PHARMA INC
Parenteral Formulations Of Dopamine Agonists
ActiveUS20130197005A1Reducing elevated cardiovascular-related inflammatory factorsBiocideMetabolism disorderParenteral Dosage FormMedicine
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
Owner:VEROSCI
Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
Compositions and methods for modulation of the suppressive activity of CD4+CD25+regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff) are provided. An agent selected from: (i) dopamine; (ii) a dopamine precursor; (iii) a D1-R agonist; (iv) a D2-R antagonist; (v) a combination of (i) and (ii); or (vi) a combination of (i), (ii) or (iii) with (iv), down-regulates the suppressive activity of Treg and is useful for treatment of cancer. An agent selected from (i) a dopamine D2-R agonist, (ii) a dopamine D1-R antagonist, and (iii) a combination of (i) and (ii), up-regulates the suppressive activity of Treg and is useful for treatment of an autoimmune disease or for controlling graft rejection in tissue / organ transplantation.
Owner:YESA RES & DEV AT THE WEIZMANN INST OF SCI
Methods of treating patients suffering from movement disorders
ActiveUS20060178379A1Reducing and suppressing adverse effectiveness of L-DOPAShorten closing timeBiocideNervous disorderAdenosineDisease patient
Owner:KYOWA HAKKO KIRIN CO LTD
Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
InactiveUS20130296324A1Enhance health and appearanceFacilitating accelerating healingBiocideNervous disorderDiseaseSynaptic cleft
The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.
Owner:HELD JERRY M
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
ActiveUS9352025B2Eliminate side effectsImprove blood sugar controlPeptide/protein ingredientsHeterocyclic compound active ingredientsPhases of clinical researchDopamine agonist
Owner:VEROSCI
Combination Of Dopamine Agonists Plus First Phase Insulin Secretagogues For The Treatment Of Metabolic Disorders
ActiveUS20150024995A1Good blood pressureImpaired glucoseBiocidePeptide/protein ingredientsDopamine agonistMetabolic disorder
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
Owner:VEROSCI
Treatment or Prevention of Ovarian Hyperstimulation Syndrome (Ohss) Using a Dopamine Agonist
InactiveUS20080293693A1Preventing ovarian hyperstimulation syndromeBiocideOrganic chemistryPhysiologyDopamine
Disclosed herein is a method for preventing ovarian hyperstimulation syndrome in a subject by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. Also disclosed herein is a method for treating ovarian hyperstimulation syndrome by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier.
Owner:FERRING INT CENT SA
New and efficient process for the preperation of cabergoline and its intermediates
This invention relates to a new and efficient process for the production of dopamine agonists such as Cabergoline and the intermediates thereof.
Owner:APOTEX PHARMACHEN INC
Methods of identifying and treating responders to dopamine agonist therapy
The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE / NE metabolites: dopamine / dopamine metabolites, (c) NE and serotonin, (d) NE / NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE / NE metabolites and serotonin metabolites, or (g) NE is / are greater than about 30% over normal level; or dopamine / dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg / dl and / or said patient has hypertension. The present invention is also directed to treating identified patients with dopamine agonist therapy.
Owner:VEROSCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com